Survival benefit of deceased donor kidney transplantation versus continued dialysis
A more visual summary of the target trial emulation and relevant context (just 7 images to look at!). Infographics by Anca Stefan and Cristina Popa
Day 3 : yet another IgA trial, and we are back with some flozin news: in ADPKD, their effect on hemoglobin, and on BP (with finerenone)
Day 2 was less exciting: we cover 1 IgA trial (Ravulizumab) along with another calcimimetic, and a pentoxifylline meta-analysis.
Day of Kidney Week 2026. The NephJC crew discusses 6 studies, including some blockbustr IgA news.
This week, we will discuss whether decreased donor transplantation improves mortality in all patients. In this target trial emulation standard donor, extended donor, donation after brain death and donation after cardiac death outcomes are compared across age groups with different co-morbid conditions.
A more visual summary of the target trial emulation and relevant context (just 7 images to look at!). Infographics by Anca Stefan and Cristina Popa
A more visual summary of the trial and relevant context (just 6 images to look at!). Infographics by Farah Wehbe
A more visual summary of the trial and relevant context (just 6 images to look at!). Infographics by Daniel Ramirez and Urvashi Khan
A more visual summary of the trial and relevant context (just 6 images to look at!). Infographics by Andreea Manolea
Bonus: more on finerenone in proteinuric CKD universe- visuals by Cristina Popa
A more visual summary of the trial and relevant context (just 6 images to look at!). Infographics by Cristina Popa
A more visual summary of the trial and relevant context (just 6 images to look at!). Infographics by Cristina Popa
NephJC continues to host its live journal clubs and real-time discussions on Bluesky where open dialogue, shared learning, and critical appraisal are central to what we do. For now, our scheduled chats and discussions will continue on Bluesky.
We are also expanding our presence on Instagram with a complementary goal. Instagram allows us to connect with nephrologists and the public who may not be active on X or Bluesky but who are still interested in practice-relevant research, methodology, and staying informed on ongoing NephJC activities. For many clinicians, Instagram serves as an accessible entry point rather than a space for in-depth discussion.
The NephJC editorial team recognizes that Instagram does not allow for the same type of open, back-and-forth dialogue that defines our journal clubs. We are not aiming to replicate that experience there. Instead, we see Instagram as a way to highlight important studies, share key concepts, and guide interested readers toward platforms where deeper discussion and engagement are possible.
Our commitment to thoughtful, inclusive, and rigorous discussion remains the same. Instagram is simply another way to welcome more colleagues into the NephJC community.